Last updated: May 27, 2026
What companies supply FEMRING estradiol acetate vaginal delivery in the US and internationally?
Answer (direct): FEMRING’s supply is tied to the marketing authorization holder and finished-dose manufacturers listed on regulatory filings and product labels, with lower-tier suppliers typically disclosed through Drug Master Files (DMFs) for the API and certain critical excipients/components. The documented, decision-grade supplier set is the finished-dose manufacturer(s) and packaging/labeler plus any DMF-linked component manufacturers that appear in FDA/foreign regulatory review documents and product dossiers.
What is FEMRING’s marketed label entity?
FEMRING is marketed in the US under the labeler shown on the FDA label/registration. In many markets, the brand is carried by Organon or an Organon successor/affiliate; the US labeler has changed over time via corporate transactions and distribution agreements. The only supplier facts that are consistently robust are:
- Finished-dose manufacturer and packaging site(s) disclosed on FDA label sections (when listed).
- DMF-driven suppliers disclosed in chemistry/manufacturing review materials, where available.
What international markets matter for supplier mapping?
Supplier structure differs by region because:
- Finished dose is often manufactured in a smaller number of sites and distributed to multiple territories.
- Some territories use local packaging/labeling even when the drug product manufacturing is centralized.
- EU dossier holders may list different responsible manufacturers than US labelers.
Which finished-dose manufacturing sites make FEMRING?
Answer (direct): Finished-dose supply is concentrated in a limited set of GMP manufacturing sites that are named in regulatory product listings and the manufacturing section of the label or dossier. These sites are the most reliable “supplier” entities for procurement, tech transfer, and regulatory risk mapping.
How to treat “supplier” for a vaginal controlled-release system
For FEMRING, supplier analysis should distinguish:
- Drug substance (estradiol acetate) suppliers: typically API producers or DMF holders.
- Drug product (vaginal system) manufacturing: assembly and sterilization/containment steps for the controlled-release vaginal delivery form.
- Packager/labeler: often separate from final assembly.
Manufacturing risk hotspots to evaluate
- Consistency of controlled-release performance across process changes.
- Patented delivery-system architecture that constrains generic replication routes and may restrict outsourcing options for reverse engineering.
What drug substance and key component suppliers exist for estradiol acetate vaginal systems?
Answer (direct): Public-facing supplier lists for FEMRING components are frequently incomplete at the lower-tier vendor level. The actionable supplier categories are:
- API supply via DMF (estradiol acetate)
- Critical excipient or polymer supply where DMFs or restricted-use manufacturing statements exist
- Packaging components (applicator or pouching components) sourced through controlled packaging vendors
DMF-centric supplier mapping (most actionable path)
Where available, the supplier set should be anchored to:
- DMF number(s) tied to estradiol acetate or critical excipients
- The named DMF holder/manufacturer responsible for those submissions
This approach prevents the common error of listing generic chemical brokers that do not actually hold regulatory documentation for clinical/commercial supply.
How many patents and who owns manufacturing and formulation IP for FEMRING suppliers to know?
Answer (direct): A supplier should treat FEMRING’s delivery system as constrained by:
- Formulation and controlled-release architecture IP (materials, geometry, rate-controlling design)
- Method-of-manufacture IP (assembly, compression, coating, release profiling)
- Use and dosing regimen IP (where still active in some jurisdictions)
Supplier selection should therefore be evaluated against:
- Whether a candidate manufacturer can demonstrate freedom-to-operate for the delivery system design
- Whether any tech transfer or contract manufacturing agreement includes IP clauses covering design authority and process confidentiality
What is the FDA regulatory status of FEMRING and what does it imply for supplier disclosures?
Answer (direct): FEMRING is an FDA-approved brand product; supplier disclosures in practice are governed by:
- The FDA listing of drug product manufacturers
- Any DMFs referenced in FDA review for product-specific chemistry and manufacturing controls
What do FDA records typically show that procurement can use?
- Finished-dose manufacturer and packager names (from label/registration records)
- If referenced: DMF holder names for API/excipients
- Application type and reference product relationships (useful for understanding the development lineage)
What generic entry risks exist for FEMRING suppliers changing the supply chain?
Answer (direct): Generic entry risk hinges on:
- Remaining Orange Book listed patents (if any are tied to FEMRING)
- Whether applicants can design around delivery-system and formulation patents without infringing manufacturing methods
- Whether the FDA accepts bioequivalence for the vaginal delivery platform as designed
For suppliers, the main business risk is not only infringement; it is also manufacturing reliability under tight release specifications typical for controlled-release vaginal systems.
Who has been associated with FEMRING supply through corporate transactions and licensing?
Answer (direct): FEMRING supply relationships have shifted with:
- Brand ownership transitions among women’s health and hormone therapy divisions
- Contract manufacturing relationships that may persist across labeler changes
- Regional distribution agreements that move finished goods between affiliates
Supplier diligence should map:
- The current labeler and its corporate structure
- The current finished-dose manufacturer and any long-term manufacturing agreements
- Whether any prior outages or recalls involved specific manufacturing sites
Key supplier short-list framework (what to verify before signing a supply agreement)
Answer (direct): Use a supplier diligence template that checks:
- GMP site that manufactures FEMRING vaginal systems
- DMF linkage for estradiol acetate and critical excipients (documented, not broker-based)
- Packaging component sourcing for applicator compatibility and patient usability
- Release testing capability specific to controlled-release performance
- Regulatory history for the manufacturing site (inspection outcomes and remediation records)
Key Takeaways
- “Suppliers for FEMRING” is best defined by (a) finished-dose manufacturers, (b) packager/labeler entities, and (c) DMF holders for estradiol acetate and critical components.
- Lower-tier component vendor names often are not publicly enumerated; the decision-grade path is DMF-anchored supplier identification plus GMP site mapping from regulatory listings.
- For contract manufacturing or sourcing changes, the binding constraints are the delivery-system controlled-release architecture and any formulation/method IP linked to FEMRING’s vaginal system design.
FAQs
- What finished-dose manufacturer sites produce FEMRING estradiol acetate vaginal systems in the US?
- Does FEMRING use Drug Master Files (DMFs) for estradiol acetate or key excipients, and who are the DMF holders?
- Which organizations act as packager and labeler for FEMRING, and how does that affect sourcing?
- What types of formulation and method patents restrict contract manufacturing of FEMRING-like vaginal systems?
- How do FEMRING supply-chain changes impact FDA release testing and controlled-release equivalence?
References
(No citable source material was provided in the prompt, and no drug-label/regulatory or DMF-specific sources can be cited without risking fabrication.)
